Recent News

• 03.25.2026 - Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
• 03.18.2026 - Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026
• 12.10.2025 - Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology
• 11.12.2025 - Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
• 11.05.2025 - Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025
• 10.24.2025 - Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference
• 10.08.2025 - Journey Medical Corporation to Participate in October 2025 Investor Conferences
• 09.03.2025 - Journey Medical Corporation to Participate in September 2025 Investor Conferences

Recent Filings

• 03.26.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.25.2026 - EX-99.1 EX-99.1
• 03.25.2026 - 8-K Current report
• 01.23.2026 - 424B3 Prospectus [Rule 424(b)(3)]
• 01.23.2026 - 424B3 Prospectus [Rule 424(b)(3)]
• 01.21.2026 - EFFECT Notice of Effectiveness
• 01.15.2026 - S-3 Registration statement under Securities Act of 1933
• 12.30.2025 - DRS Draft Registration Statement
• 11.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.12.2025 - 8-K Current report